Anika Therapeutics (ANIK) Other Accumulated Expenses (2011 - 2026)

Anika Therapeutics (ANIK) has 15 years of Other Accumulated Expenses data on file, last reported at $479000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $479000.0, down 38.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $479000.0 (down 38.27% YoY), and the FY2025 annual result was $468000.0, down 38.82% from the prior year.
• Other Accumulated Expenses rose to $479000.0 in Q1 2026 per ANIK's latest filing, from $468000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.1 million in Q1 2022 and troughed at $338000.0 in Q4 2023.
• A 5-year average of $611941.2 and a median of $517000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses plunged 97.14% in 2022, then surged 126.33% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $510000.0 in 2022, then slumped by 33.73% to $338000.0 in 2023, then jumped by 126.33% to $765000.0 in 2024, then plunged by 38.82% to $468000.0 in 2025, then gained by 2.35% to $479000.0 in 2026.
• Business Quant data shows ANIK's Other Accumulated Expenses at $479000.0 in Q1 2026, $468000.0 in Q4 2025, and $750000.0 in Q3 2025.